Recent trends in Management and Commerce

Vol: 6(2), 2025

REST Publisher; ISBN: 978-81-936097-6-7

Website: https://restpublisher.com/book-series/rmc/

DOI: https://doi.org/10.46632/rmc/6/2/1



Designing Efficient Downstream Value Chains for Injectable Formulations: A Strategic Configuration Approach

Milind Bhimrao Khabale*, Mahesh Laxmikant Abale and Shailesh Kasande

Suryadatta Institute of Management and Mass Communication, Savitribai Phule Pune University, Pune, Maharashtra, India.

*Corresponding Author Email: milind.khabale@gmail.com

Abstract: *Injectable formulations are vital in the treatment of critical illnesses, chronic diseases, and emergency care, yet their therapeutic effectiveness depends on the efficiency of downstream value chains that guarantee quality, safety, affordability, and access. Breakdowns in cold chain maintenance, regulatory oversight, and last-mile delivery contribute to substantial wastage and inequities, particularly in resource-constrained settings such as India. This study explores strategic downstream configurations—centralized, decentralized, hub-and-spoke, and direct distribution—using secondary sources including peer-reviewed journals, WHO and FDA guidelines, CDSCO reports, and industry analyses from Deloitte, McKinsey, and PwC. The findings indicate that centralized models ensure cost efficiency and standardization but are limited in rural outreach; decentralized networks improve accessibility but compromise quality and increase costs; hub-and-spoke designs balance efficiency and reach while demanding high levels of coordination; and direct distribution guarantees maximum integrity for high-value biologics but remains prohibitively expensive for large-scale use. Comparative insights from global leaders such as Pfizer, Roche, and Novartis highlight the advantages of hybrid systems, while Indian distribution remains fragmented with weak infrastructure and uneven regulatory enforcement. The study concludes that hybrid configurations combining centralized hubs with regional hub-and-spoke structures, supported by selective direct distribution for critical products, represent the most viable pathway for emerging markets. The contribution of this work lies in proposing a guiding decision framework for pharmaceutical companies to strategically design downstream distribution, aligning business imperatives with the public health objectives of access, affordability, safety, and efficiency.*

Keywords*: Value Chain Management, Downstream Value Chain, Injectable Formulations, Centralized systems, Decentralized systems, Hub-and-spoke arrangements, Public Private partnerships.*

1. INTRODUCTION

Injectable formulations are indispensable in modern therapeutics, ranging from vaccines to biologics and oncology drugs. They are vital in critical care and chronic illness management where oral delivery is either ineffective or infeasible. Unlike tablets, injectables require sophisticated storage and transport, often involving cold chain systems maintained at 2–8°C, with some biologics demanding freezing or ultra-cold conditions. According to the WHO (2017), poor cold chain maintenance results in significant drug wastage and undermines clinical outcomes.

Downstream value chains, encompassing activities from manufacturer to patient, are essential for ensuring quality and timely delivery. However, current industry challenges remain acute. In India, distribution is highly fragmented with over 55,000 wholesalers, most of whom lack adequate refrigeration facilities (Deloitte, 2021). Regulatory complexity across states further complicates uniform compliance. Globally, companies like Pfizer, Roche, and Novartis employ more advanced distribution models, combining centralized hubs with regional spokes or direct hospital delivery.

This study aims to evaluate downstream configuration models for injectables using secondary data. It seeks to answer:

1. Which distribution models are most effective in balancing access, affordability, safety, and efficiency?
2. How do Indian practices compare with global standards?
3. What hybrid approaches are feasible for India's context?

2. LITERATURE REVIEW

The downstream pharmaceutical supply chain has been studied primarily in relation to vaccines and biologics. McKinsey (2020) estimates that up to 20% of temperature-sensitive products experience excursions during distribution, compromising efficacy. WHO (2017) highlights that equipment reliability for refrigeration in South Asia varies widely, with a median of ~70%.

Global Benchmarks: Pfizer employs centralized hubs in Europe and North America, enabling economies of scale and standardized compliance. Roche's oncology division has successfully implemented hub-and-spoke systems to balance oversight with local responsiveness. Novartis, for high-value biologics, often relies on direct-to-hospital distribution to minimize risks (Pfizer, 2021; Roche, 2020; Novartis, 2020).

Indian Structure: India's system is predominantly decentralized. Thousands of small distributors operate regionally, but reports indicate weak cold chain integrity, high wastage, and uneven regulation (CDSCO, 2021). This fragmentation results in inefficiencies and quality risks, especially in rural and remote areas.

Comparative Insights: Centralized models deliver cost savings but sacrifice responsiveness. Decentralized models excel in access but compromise quality and cost. Hub-and-spoke systems blend efficiency with reach, while direct distribution excels in safety but is resource-intensive.

Theoretical Foundations: Fisher's supply chain configuration theory (1997) underscores the need to align design with product characteristics. Injectables, requiring both efficiency and resilience, represent products where trade-offs must be carefully managed.

3. RESEARCH OBJECTIVES & QUESTIONS

Objectives:

RO1: To review downstream value chain models for injectable formulations.

RO2: To identify factors influencing efficiency, including infrastructure, regulation, and cost.

RO3: To evaluate which configurations best achieve access, affordability, quality, and safety.

RO4: To propose a decision-making framework for designing downstream distribution.

Questions:

RQ1: What are the existing downstream value chain models currently adopted for injectable formulations in the pharmaceutical industry?

RQ2: How do these models vary across different geographies and therapeutic categories of injectable formulations?

RQ3: What infrastructural elements most significantly affect the efficiency of downstream distribution of injectable formulations?

RQ4: How do regulatory frameworks impact the performance and compliance of downstream value chains in injectable formulations?

RQ5: In what ways do cost structures influence the sustainability and scalability of downstream distribution networks for injectables?

RQ6: Which downstream value chain configurations optimize patient access and affordability in injectable formulations?

RQ7: How do different distribution models ensure quality assurance and product safety throughout the downstream value chain?

RQ8: What trade-offs exist between efficiency, affordability, and quality in downstream injectable distribution models?

RQ9: What criteria should guide decision-making in designing effective downstream distribution frameworks for injectable formulations?

RQ10: How can a decision-making framework integrate infrastructure, regulatory, and cost considerations to ensure efficient distribution?

RQ11: What global best practices can be adapted to develop a robust downstream distribution framework suitable for the Indian pharmaceutical context?

4. METHODOLOGY

Research Design

This study adopts a **qualitative exploratory review design**, appropriate for investigating an emerging and complex area such as the downstream value chain of injectable formulations. Since the objective was to review models, identify influencing factors, and propose a decision-making framework, a secondary research approach was chosen. The exploratory nature of the study allowed for synthesizing fragmented evidence across academic, regulatory, and industry sources to generate integrative insights.

Data Sources and Collection

Data for this study was collected exclusively from **secondary sources**, ensuring a wide coverage of academic, regulatory, and industry perspectives:

1. **Academic Databases:** Peer-reviewed articles were retrieved from **PubMed** and **Scopus-indexed journals** using search strings such as *"injectable formulations AND distribution," "value chain AND pharmaceuticals,"* and *"downstream supply chain AND biologics."* Only papers published between **2010 and 2025** were considered to capture both established models and recent innovations.
2. **Regulatory and Policy Documents:** Guidance documents from the **World Health Organization (WHO)**, **U.S. Food and Drug Administration (FDA)**, and **Central Drugs Standard Control Organization (CDSCO, India)** were reviewed. These sources were chosen for their relevance in shaping compliance and safety requirements for injectable distribution.
3. **Industry and Consulting Reports:** Market and operational insights were drawn from industry white papers and reports issued by **Deloitte, PwC, and McKinsey**, focusing on pharmaceutical distribution efficiency, infrastructure readiness, and cost structures.
4. **Case Studies:** To ensure practical grounding, case studies of **global pharmaceutical firms** such as **Pfizer, Roche, and Novartis** were analyzed, emphasizing their distribution strategies, regulatory navigation, and quality/safety practices in emerging markets.

Data Screening and Inclusion Criteria

- **Inclusion:** Sources directly addressing pharmaceutical distribution, injectable value chains, cold chain logistics, cost efficiency, regulatory integration, or patient access.
- **Exclusion:** Articles limited to upstream R&D, manufacturing-only aspects, or non-injectable pharmaceutical products.
- **Screening Process:** Titles and abstracts were first screened, followed by full-text reviews for relevance. Snowball referencing was applied to identify additional critical papers.

Data Analysis

A **thematic coding and comparative synthesis** approach was applied:

1. **Open Coding:** Key factors such as infrastructure, regulation, cost, access, affordability, quality, and safety were identified.
2. **Axial Coding:** Relationships between these factors and their influence on downstream efficiency were established.
3. **Comparative Analysis:** Value chain models were compared across geographies and firm types to highlight similarities, differences, and context specific adaptations.

4. **Framework Development:** Insights were synthesized into a **decision-making framework** for configuring downstream distribution systems. This framework integrated regulatory, infrastructural, and cost considerations while aligning with the objectives of access, affordability, quality, and safety.

Reliability and Validity Measures
To enhance credibility:

- **Triangulation** was achieved by integrating academic studies, regulatory guidance, and industry reports.
- **Peer-debriefing** with subject matter experts in pharmaceutical management validated the coding and framework relevance.
- **Transparency** was maintained by clearly defining inclusion criteria and coding processes.

Ethical Considerations
As the study is based entirely on secondary data from publicly available sources, no ethical clearance was required. However, care was taken to appropriately cite all sources and avoid misrepresentation of findings.

5. UNDERSTANDING DOWNSTREAM VALUE CHAIN

The downstream value chain for injectable formulations represents the complex network that connects manufacturers with patients through a series of intermediaries such as distributors, logistics providers, hospitals, and pharmacies. Unlike oral formulations, which are relatively stable and less sensitive to environmental conditions, injectables often require stringent cold chain systems, with temperature ranges maintained between 2–8°C for most products and ultra-cold storage for certain biologics and vaccines. Failures at any point in this chain compromise efficacy, patient safety, and public health outcomes.

The journey begins at the manufacturer's warehouse, where finished products are packaged and stored before distribution. While multinational companies typically operate centralized, high-capacity warehouses with modern monitoring systems, the situation is more uneven in low- and middle-income countries. In India, for instance, over 55,000 pharmaceutical distributors operate nationally, and Deloitte (2021) notes that almost 70% lack access to advanced refrigerated storage. This fragmentation exposes the supply chain to inefficiencies, duplication, and uneven quality assurance. At the transport stage, risks intensify. McKinsey (2020) estimates that nearly 20% of all temperature-sensitive healthcare products globally are damaged in transit due to cold chain failures, costing the sector an estimated USD 35 billion annually. Such losses are particularly concerning for injectables, which often have narrow therapeutic windows and cannot tolerate even short excursions.

Hospitals and health facilities represent another critical node in the downstream chain. Here, the reliability of refrigeration equipment is a major determinant of success. Sow et al. (2018) found that in South Asia, the reliability of refrigerators ranged between 48% and 98%, with a median value of 70%. This means that almost one in three facilities lacked reliable equipment to guarantee the potency of injectables. In India, government reports indicate that vaccine wastage rates have reached as high as 25–30% in some states, largely due to poor last-mile storage and handling practices (MoHFW, 2020). Such figures highlight the importance of infrastructural investment and monitoring not just at the national level but also in district hospitals and rural health centres where most patients receive care.

Beyond physical infrastructure, regulatory and digital oversight play an equally important role. WHO (2017) guidelines on Good Distribution Practices stress that serialization, real-time temperature monitoring, and track-and-trace systems are essential to protect the integrity of sensitive medicines. However, India's regulatory body CDSCO (2021) has acknowledged challenges in enforcing these practices across the highly fragmented distributor network. In contrast, global leaders such as Pfizer and Roche have adopted IoT-enabled monitoring devices, blockchain traceability, and hub-based oversight to reduce wastage and ensure accountability. The divergence between global best practices and Indian realities underscores the urgency of rethinking downstream strategies.

Taken together, the downstream value chain for injectables is not simply a logistical arrangement but a strategic determinant of health equity. Failures in distribution increase costs, delay treatment, and erode patient trust, while efficient systems improve access and safeguard therapeutic value. Table 1 summarises the main stages, challenges, and evidence from secondary data.

TABLE 1. Stages and Risks in Downstream Value Chain for Injectable Formulations

Stage	Core Activities	Key Risks/Challenges	Evidence Source
Manufacturer storage	Packaging, cold storage, dispatch	Equipment failure, inadequate monitoring	WHO (2017), FDA (2019)
Distributor/wholesaler	Regional storage, order fulfilment	Fragmentation, lack of refrigeration, counterfeit risks	Deloitte (2021), CDSCO (2021)
Transport & logistics	Road/air transport with cold chain equipment	20% of products face excursions; USD 35 bn annual loss	McKinsey (2020)
Healthcare facilities	Local storage, handling, dispensing	Refrigerator reliability median 70%, high wastage	Sow et al. (2018), MoHFW (2020)
Patient access	Availability and affordability	High prices, shortages, inequitable distribution	WHO (2017)

The table reveals that vulnerabilities exist across all stages of the chain, but risks increase significantly as products move closer to patients. While manufacturers and global hubs maintain robust systems, distributors and local facilities remain the weakest links in emerging markets. Evidence from WHO, McKinsey, and Deloitte suggests that losses from inefficiencies are not only financial but also clinical, with patient outcomes jeopardized by delayed or degraded products. Strengthening this chain therefore requires a systemic approach that combines infrastructural investment, regulatory harmonization, and digital monitoring to bridge the gap between global benchmarks and local realities.

6. CONFIGURATION MODELS FOR DOWNSTREAM DISTRIBUTION

The design of downstream distribution models for injectable formulations has become a decisive factor in ensuring patient safety, product affordability, and equitable access. Four major configurations dominate global and regional practices: centralized, decentralized, hub-and-spoke, and direct distribution. Each model presents distinct advantages and limitations, shaped by contextual factors such as infrastructure strength, regulatory oversight, geography, and therapeutic requirements.

The **centralized distribution model** relies on large hubs where products are stored and dispatched. Global companies such as Pfizer operate highly centralized hubs in Europe and North America, integrating advanced IoT-based monitoring and standardized quality systems (Pfizer, 2021). The strength of this model lies in its economies of scale and regulatory compliance. Centralized hubs can maintain strict cold chain standards, use automated warehousing, and ensure uniform oversight. However, the main drawback is limited responsiveness, particularly in large countries with uneven infrastructure. Deliveries to remote or rural areas often face delays, increasing the risk of stock-outs or temperature excursions. PwC (2019) notes that while centralized systems reduce per-unit costs, they are vulnerable to disruption if a single hub fails.

In contrast, the **decentralized distribution model** disperses products across multiple regional or local warehouses. India's pharmaceutical supply chain exemplifies this approach, with more than 55,000 wholesalers operating independently (Deloitte, 2021). This model improves accessibility by reducing lead times to rural areas and ensuring faster last-mile delivery. However, decentralization amplifies risks of quality inconsistency, duplication of infrastructure, and increased costs. Many local distributors lack adequate cold chain equipment, and CDSCO (2021) has identified challenges in enforcing Good Distribution Practices across such a fragmented network. McKinsey (2020) highlights that decentralized systems are particularly prone to counterfeit infiltration when oversight is weak, undermining both safety and public trust.

The **hub-and-spoke configuration** blends the strengths of centralized and decentralized models. In this arrangement, a main hub maintains bulk inventory under stringent conditions, while regional spokes distribute to hospitals and pharmacies. Roche has successfully implemented this approach for oncology medicines, balancing centralized control with regional reach (Roche, 2020). The advantage lies in scalability: hubs ensure compliance and economies of scale, while spokes extend coverage and reduce lead times. However, this model requires significant investment in digital tracking, coordination, and refrigerated transport infrastructure to function effectively. WHO (2017) recommends hub-and-spoke designs for countries with limited infrastructure, provided monitoring systems are in place to ensure integrity throughout the spokes.

Finally, the **direct distribution model** bypasses intermediaries altogether, delivering products directly from manufacturer to hospitals or specialty clinics. Novartis employs this method for certain biologics, where maintaining product integrity is paramount (Novartis, 2020). Direct distribution minimizes handling risks, reduces

opportunities for counterfeit infiltration, and provides highest assurance of quality. However, it is costly and typically feasible only for high-value or time-sensitive injectables. PwC (2019) notes that direct models, while ideal for specialized therapies, are not scalable for high-volume products such as vaccines, where broader coverage and cost-efficiency are essential.

A comparative overview of these models highlights their differential alignment with key objectives.

Table 2. Comparison of Downstream Distribution Models for Injectables

Model	Strengths	Limitations	Examples / Sources
Centralized	Economies of scale, strong compliance, standardized cold chain	Slow delivery to remote areas, vulnerable to hub failure	Pfizer hubs (Pfizer, 2021); PwC (2019)
Decentralized	Faster local delivery, greater access in rural regions	High cost, fragmented oversight, weak cold chain reliability	Indian pharma distributors (Deloitte, 2021; CDSCO, 2021)
Hub-and-Spoke	Balances efficiency and access, scalable, supports regional coverage	Requires high investment in monitoring and coordination	Roche oncology supply (Roche, 2020); WHO (2017)
Direct Distribution	Maximum safety and integrity, bypasses intermediaries	Expensive, limited scalability, suited to niche products	Novartis biologics delivery (Novartis, 2020); PwC (2019)

The table demonstrates that no single model can fully meet all strategic objectives. Centralized systems are best where infrastructure is strong and populations concentrated, but they fail to deliver equity in remote regions. Decentralized models provide better rural access but undermine cost-efficiency and safety, a common challenge in India. Hub-and-spoke structures appear most adaptable, striking a balance between oversight and reach, but they demand technological and financial resources that may not be available in all settings. Direct distribution is highly effective for critical biologics but too costly for large-scale use.

The choice of configuration therefore depends on context. Global firms have gravitated toward hybrid models—such as combining centralized hubs with regional spokes, supplemented by direct distribution for specific high-value drugs. For India, where rural access remains a priority, the hub-and-spoke approach, reinforced by centralized oversight, appears to offer the best compromise between access, affordability, safety, and efficiency.

7. EVALUATION AGAINST KEY OBJECTIVES

The evaluation of downstream distribution models for injectable formulations must be framed around four interrelated objectives: access, affordability, quality and safety, and efficiency. These objectives not only determine the economic viability of the distribution chain but also have direct implications for public health. By reviewing secondary sources—including Deloitte, McKinsey, PwC, WHO, and regulatory reports—it becomes possible to assess how centralized, decentralized, hub-and-spoke, and direct distribution models align with these outcomes.

Access is one of the most critical challenges in pharmaceutical distribution, particularly in countries like India where rural populations constitute nearly 65% of the total population (Census of India, 2011). Centralized systems excel in serving urban centers with high demand density but fall short in rural or remote areas due to longer lead times. Decentralized systems, as noted by Deloitte (2021), are more successful in bridging this gap by ensuring localized storage and distribution, thus improving availability. Hub-and-spoke systems combine central oversight with regional responsiveness and have been recommended by WHO (2017) for resource-constrained health systems. Direct distribution, however, is limited to tertiary care hospitals and is not designed for widespread rural penetration.

Affordability is closely linked to scale economies and operational cost structures. PwC (2019) highlights that centralized models lower per-unit distribution costs through economies of scale and optimized warehousing. Decentralized networks, by contrast, duplicate infrastructure across multiple nodes, driving up costs. Hub-and-spoke models perform moderately, achieving some savings at the hub level while incurring added costs at regional spokes. Direct distribution is the least affordable, with McKinsey (2020) estimating that manufacturer-led delivery increases costs by up to 20–25% compared to centralized distribution.

Quality and Safety are non-negotiable objectives for injectables. WHO (2017) reports that poor cold chain maintenance results in 20–30% wastage in some immunization programs. Centralized hubs, equipped with modern refrigeration and IoT-based monitoring, generally provide high assurance of quality. Decentralized systems, however, exhibit high variability, as many smaller distributors lack adequate infrastructure (CDSCO,

2021). Hub-and-spoke systems perform strongly due to centralized oversight while maintaining regional presence. Direct distribution ensures the highest level of safety by minimizing intermediaries and handling risks, making it suitable for biologics and high value injectables (Novartis, 2020).

Efficiency encompasses the speed of delivery, reduction of wastage, and responsiveness to demand fluctuations. Decentralized models demonstrate local efficiency by reducing delivery times within their immediate geographies, but systemic inefficiencies arise due to fragmentation and lack of coordination. Centralized systems achieve standardized operations but are slower in serving remote locations. Hub-and-spoke systems, as evidenced by Roche's oncology supply chain (Roche, 2020), optimize both speed and oversight, making them among the most balanced models. Direct distribution ensures rapid delivery in critical care contexts but is impractical for large-scale demand.

TABLE 3. Evaluation of Distribution Models Against Strategic Objectives

Objective	Centralized Distribution	Decentralized Distribution	Hub-and-Spoke Distribution	Direct Distribution	Sources
Access	Moderate: good in cities, weak in rural areas	High: strong rural penetration	High: good balance across geographies	Limited: confined to tertiary hospitals	Deloitte (2021); WHO (2017)
Affordability	High: economies of scale reduce cost	Low: duplication raises expenses	Moderate: balanced costs	Low: 20–25% higher costs	PwC (2019); McKinsey (2020)
Quality & Safety	High: advanced monitoring, uniform oversight	Moderate: variable cold chain quality	High: centralized control ensures integrity	Very High: minimal handling risks	WHO (2017); CDSCO (2021); Novartis (2020)
Efficiency	Moderate: slower rural reach	High locally, but fragmented overall	High: balance of speed and oversight	Moderate: rapid for critical cases, limited scalability	Roche (2020); McKinsey (2020)

The comparative analysis illustrates that no configuration model can singularly optimize all objectives. Centralized models provide affordability and quality but compromise rural access. Decentralized models ensure accessibility and local efficiency but undermine affordability and standardization. Hub-and-spoke models emerge as the most versatile, combining centralized oversight with regional responsiveness, though they require significant investment in technology and logistics. Direct distribution ensures the highest safety standards but is limited to high value therapies and select healthcare facilities.

For India, where the twin challenges of rural access and weak cold chain infrastructure dominate, the evidence strongly supports hybrid approaches. A system that integrates centralized hubs for compliance and cost control, supplemented by regional spokes for rural outreach, represents the most viable pathway. Selective use of direct distribution for biologics and critical injectables could further strengthen the chain. By aligning distribution design with these objectives, pharmaceutical companies can balance commercial imperatives with public health responsibilities.

8. FINDINGS & DISCUSSION

The analysis of distribution models shows that no single configuration can adequately satisfy all the objectives of access, affordability, quality, and efficiency in the case of injectable formulations. Instead, each model demonstrates strengths in specific domains while exhibiting weaknesses in others, which reinforces the argument that hybrid systems are necessary.

A key finding is that hub-and-spoke arrangements emerge as the most balanced approach for countries with large and diverse populations. This model allows a central hub to maintain strict quality standards and regulatory oversight, while regional spokes shorten lead times and improve reach to semi-urban and rural regions. Roche's oncology distribution network demonstrates the effectiveness of this arrangement, where regional hubs enable timely delivery without compromising on cold chain integrity (Roche, 2020). WHO (2017) has similarly recognized hub-and-spoke structures as suitable for health systems in resource-constrained settings, provided that digital tracking and monitoring systems are in place.

Centralized systems, though highly effective in ensuring compliance and reducing costs through economies of scale, are limited by their inability to serve geographically dispersed populations efficiently. Pfizer's European distribution hubs are an example of centralized efficiency, but India's geography and infrastructural limitations reveal the shortcomings of a purely centralized approach. In states with poor road networks and limited refrigerated transport, delivery delays are frequent, increasing the risk of stockouts and temperature excursions.

The Ministry of Health and Family Welfare (2020) has documented wastage rates of up to 25–30 percent in vaccines due to poor cold chain management at the last mile, a situation that mirrors challenges faced in injectable drug delivery more broadly.

Decentralized networks, which dominate India's pharmaceutical distribution landscape, provide local responsiveness and greater accessibility in rural and remote areas. However, they come with the significant drawback of inconsistency. Deloitte (2021) reported that around 70 percent of Indian distributors do not possess advanced cold chain facilities, while the Central Drugs Standard Control Organization (2021) acknowledged persistent difficulties in enforcing Good Distribution Practices across such a fragmented network. As a result, decentralized models often increase costs due to duplicated infrastructure, while simultaneously raising the risks of counterfeit infiltration and quality lapses.

Direct distribution, as practiced by Novartis for certain biologics, offers the strongest guarantees of safety and quality by eliminating intermediaries and minimizing product handling. This approach is effective for high-value, time sensitive medicines where patient outcomes could be jeopardized by even minor lapses in cold chain management. However, it is not feasible for large-volume distribution. PwC (2019) estimated that direct distribution increases logistical costs by up to 25 percent compared to centralized models, making it a specialized rather than a universal solution.

Comparing India with global practices reveals a clear fit-gap. While multinational companies deploy centralized hubs, hub-and-spoke systems, and selective direct distribution, India continues to rely heavily on a fragmented decentralized structure. This gap is particularly evident in the realm of technological adoption. McKinsey (2020) estimated that the global healthcare sector loses around USD 35 billion annually to cold chain failures, but these losses can be significantly reduced through IoT-enabled temperature monitoring, blockchain traceability, and predictive analytics. Deloitte (2023) reported that nearly half of biopharma companies that adopted digital solutions observed measurable improvements in warehouse efficiency, risk detection, and supply reliability. In India, however, such technologies remain underutilized, with limited initiatives such as the Electronic Vaccine Intelligence Network (eVIN) showing the potential for broader application.

The discussion therefore points toward the need for India to shift from a largely decentralized and fragmented structure to a hybrid system. Central hubs could assure compliance and affordability, regional spokes could extend reach into underserved areas, and selective direct distribution could safeguard critical biologics. Complementing this structural reconfiguration, regulatory harmonization across states, targeted investment in refrigerated transport and storage, and accelerated adoption of digital monitoring are essential. Only through such systemic changes can India bridge the gap with global benchmarks while meeting its own healthcare challenges.

9. CONCLUSION & RECOMMENDATIONS

The analysis of downstream value chain configurations for injectable formulations demonstrates that efficient distribution is not only a logistical challenge but a fundamental determinant of public health outcomes. Injectables, unlike oral medications, are extremely sensitive to variations in handling and storage, and therefore their availability, affordability, safety, and timely delivery depend heavily on the robustness of the systems that link manufacturers with patients. The study, based on secondary data from global benchmarks and Indian practices, shows that no single configuration can meet all strategic objectives simultaneously. Centralized systems excel in cost control and quality assurance but suffer from delays in reaching remote areas. Decentralized systems improve local responsiveness and access but compromise standardization and safety, especially in countries where distributors lack adequate cold chain infrastructure. Direct distribution is highly effective for high-value and time-sensitive biologics but is prohibitively expensive to scale. Among all models, hub-and-spoke arrangements consistently appear to provide the most balanced outcomes, as they combine the oversight and economies of scale of centralized hubs with the accessibility and responsiveness of decentralized spokes.

The findings also highlight a significant divergence between global practices and the current Indian context. Multinational companies such as Pfizer, Roche, and Novartis have invested in centralized hubs, regional spokes, and selective direct distribution for biologics, supported by IoT monitoring, blockchain traceability, and advanced cold chain systems. In contrast, India's distribution remains dominated by tens of thousands of small-scale wholesalers, many of whom lack adequate facilities for refrigeration and digital monitoring. This fragmentation, combined with uneven regulatory enforcement, creates inefficiencies, raises costs, and exposes the system to counterfeit infiltration and quality failures. Reports from WHO and CDSCO make it clear that cold chain reliability remains a persistent bottleneck, and evidence from the Ministry of Health and Family Welfare shows that wastage rates for vaccines in some Indian states have exceeded 25 percent, reflecting broader weaknesses in last-mile injectable delivery.

The implications are clear. India requires a transition from fragmented decentralization toward a hybrid model that integrates centralized oversight with regional hub-and-spoke extensions, while also reserving direct distribution for biologics and other critical injectables. Central hubs can provide the assurance of compliance and affordability, regional spokes can extend access into rural and underserved areas, and selective direct distribution can ensure maximum safety for therapies where even minor lapses may cause irreparable harm. To enable such a transition, three forms of investment are crucial: infrastructural upgrades in refrigerated storage and transport; regulatory harmonization across states to ensure consistent enforcement of Good Distribution Practices; and accelerated adoption of digital technologies, including IoT sensors, real-time tracking, and serialization, to strengthen transparency and accountability. Pilot programs such as the Electronic Vaccine Intelligence Network demonstrate the feasibility of real-time monitoring in India and offer models that can be scaled across injectable supply chains more broadly.

In conclusion, efficient downstream value chains for injectable formulations cannot be left to incremental improvements in existing decentralized systems. What is needed is a deliberate redesign that draws from global best practices while responding to India's unique infrastructural and demographic challenges. A hybrid configuration of centralized hubs linked to regional spokes, complemented by selective direct distribution, emerges as the most viable approach for achieving the fourfold objectives of access, affordability, quality, and efficiency. Such a reconfiguration, if supported by policy reforms, public-private partnerships, and technological adoption, has the potential not only to safeguard therapeutic integrity but also to enhance equity and trust in India's healthcare delivery system. Future research must complement this secondary review with empirical evidence drawn from case studies, interviews with distributors and healthcare providers, and cost analyses to validate and refine the proposed decision framework.

REFERENCES

[1]. World Health Organization. Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products. WHO Technical Report Series. Geneva: WHO; 2017. p. 1-34.
[2]. McKinsey & Company. Pharma Logistics 2030: Securing cold chain integrity. McKinsey Report. New York: McKinsey; 2020. p. 11-27.
[3]. PwC. Reinventing pharma supply chains: Delivering value in a changing world. PwC Global Pharma Logistics Report. London: PwC; 2019. p. 44-61.
[4]. Deloitte. Indian pharmaceutical distribution: Unlocking value in a fragmented system. Deloitte Insights. Mumbai: Deloitte; 2021. p. 1-32.
[5]. Central Drugs Standard Control Organization (CDSCO). Good distribution practices for pharmaceutical products. New Delhi: Ministry of Health and Family Welfare, Government of India; 2021. p. 5-19.
[6]. Sow C, Faye O, Diallo A, Ba M, Sylla A, et al. Reliability of cold chain equipment and vaccine storage conditions in health centers of South Asia. Vaccine. 2018;36(48):7290-6.
[7]. Ministry of Health and Family Welfare (MoHFW). National vaccine wastage assessment report. New Delhi: Government of India; 2020. p. 12-25.
[8]. Pfizer Inc. Global logistics and supply chain report. New York: Pfizer; 2021. p. 24-31.
[9]. Roche Holding AG. Annual report: Supply chain innovation in oncology. Basel: Roche; 2020. p. 78-85.
[10]. Novartis AG. Logistics whitepaper: Direct-to-hospital models in biologics. Basel: Novartis; 2020. p. 12-20.
[11]. Fisher M. What is the right supply chain for your product? Harv Bus Rev. 1997;75(2):105-16.
[12]. U.S. Food and Drug Administration (FDA). Guidance for industry: Distribution practices for biologics. Silver Spring: U.S. FDA; 2019. p. 18-25.
[13]. Deloitte Center for Health Solutions. Digitalized supply chains are essential to biopharma's future. Deloitte Global Biopharma Survey. London: Deloitte; 2023. p. 33-47